Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
2,044
Views
2
CrossRef citations to date
0
Altmetric
Health Financing

Cost, healthcare utilization, and outcomes of antibody-mediated rejection in kidney transplant recipients in the US

Allyson Harta Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA;b University of Minnesota Medical School, Minneapolis, MN, USACorrespondence[email protected]
,
David Zauna Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA
,
Robbin Itzlerc CSL Behring, King of Prussia, PA, USA
,
David Schladta Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA
,
Ajay Isrania Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA;b University of Minnesota Medical School, Minneapolis, MN, USA
&
Bertram Kasiskea Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA;b University of Minnesota Medical School, Minneapolis, MN, USA
Pages 1011-1017 | Received 10 May 2021, Accepted 02 Aug 2021, Published online: 18 Aug 2021

References

  • Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2017 annual data report: kidney. Am J Transplant. 2019;19 Suppl 2:19–123.
  • Rao PS, Schaubel DE, Jia X, et al. Survival on dialysis post-kidney transplant failure: results from the scientific registry of transplant recipients. Am J Kidney Dis. 2007;49(2):294–300.
  • Purnajo I, Beaumont JL, Polinsky M, et al. Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: analysis of the BENEFIT and benefit-ext trials. Am J Transplant. 2020;20(6):1650–1658.
  • Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9(11):2520–2531.
  • Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90(1):68–74.
  • Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388–399.
  • Muduma G, Odeyemi I, Smith-Palmer J, et al. Review of the clinical and economic burden of antibody-mediated rejection in renal transplant recipients. Adv Ther. 2016;33(3):345–356.
  • Irish W, Boscoe A, Ryan MP, et al. Economic burden of antibody mediated rejection following kidney transplantation: comparative analysis using the premier hospital databse. Value Health. 2015;18(3):A187.
  • Hart A, Schladt DP, Matas AJ, et al. Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection – the long-term deterioration of kidney allograft function (DeKAF) prospective cohort study. Clin Transplant. 2021;35(7):e14337.
  • Tanriover B, Wright SE, Foster SV, et al. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc. 2008;40(10):3393–3396.
  • Wan SS, Ying TD, Wyburn K, et al. The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis. Transplantation. 2018;102(4):557–568.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.